Role of Oxidative Stress in Disease Progression in Stage B, a Pre-cursor of Heart Failure

Heart Failure Clinics

Volumn 8, Issue 1, 2012, Pages 101-111

  Bhimaraj, Arvind ^a   Tang, W H Wilson ^b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Oxidative stress; Progression of heart failure; Stage B heart failure

Indexed keywords

ADIPONECTIN; ALLANTOIN; ALLOPURINOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; MALONALDEHYDE; MATRIX METALLOPROTEINASE; METFORMIN; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; RESISTIN; ROSIGLITAZONE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ACUTE HEART INFARCTION; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIAC PATIENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LEUKOCYTE; METABOLIC DISORDER; MITRAL VALVE REGURGITATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VALVULAR HEART DISEASE;

ANIMALS; DISEASE PROGRESSION; HEART FAILURE; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 82955248175     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.08.003     Document Type: Review

References (111)

1. Sawyer D.B., Siwik D.A., Xiao L., et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002, 34(4):379-388.
2. Thannickal V.J., Fanburg B.L. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000, 279(6):L1005-L1028.
3. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108(16):1912-1916.
4. Dreher D., Junod A.F. Role of oxygen free radicals in cancer development. Eur J Cancer 1996, 32A(1):30-38.
5. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40(4):405-412.
6. Wolff S.P. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993, 49(3):642-652.
7. Cathcart M.K., McNally A.K., Morel D.W., et al. Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. J Immunol 1989, 142(6):1963-1969.
8. Cathcart M.K., Chisolm G.M., McNally A.K., et al. Oxidative modification of low density lipoprotein (LDL) by activated human monocytes and the cell lines U937 and HL60. In Vitro Cell Dev Biol 1988, 24(10):1001-1008.
9. Griendling K.K., Minieri C.A., Ollerenshaw J.D., et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994, 74(6):1141-1148.
10. Halliwell B. Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br J Exp Pathol 1989, 70(6):737-757.
11. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109(13):1594-1602.
12. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107(25):3133-3140.
13. Hare J.M., Mangal B., Brown J., et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008, 51(24):2301-2309.
14. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107(11):1486-1491.
15. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108(19):2317-2322.
16. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81(4):1161-1172.
17. Kukielka G.L., Smith C.W., LaRosa G.J., et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995, 95(1):89-103.
18. Nakamura K., Fushimi K., Kouchi H., et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998, 98(8):794-799.
19. 2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 2003, 92(2):136-138.
20. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320(14):915-924.
21. Chen E.P., Bittner H.B., Davis R.D., et al. Extracellular superoxide dismutase transgene overexpression preserves postischemic myocardial function in isolated murine hearts. Circulation 1996, 94(Suppl 9):II412-II417.
22. Wang P., Chen H., Qin H., et al. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc Natl Acad Sci U S A 1998, 95(8):4556-4560.
23. Giordano F.J., Johnson R.S. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 2001, 11(1):35-40.
24. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998, 12(2):149-162.
25. Irwin M.W., Mak S., Mann D.L., et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999, 99(11):1492-1498.
26. Engberding N., Spiekermann S., Schaefer A., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation 2004, 110(15):2175-2179.
27. Heras M., Sanz G., Roig E., et al. Endothelial dysfunction of the non-infarct related, angiographically normal, coronary artery in patients with an acute myocardial infarction. Eur Heart J 1996, 17(5):715-720.
28. Werns S.W., Walton J.A., Hsia H.H., et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989, 79(2):287-291.
29. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 1996, 275(20):1557-1562.
30. Moser M., Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996, 27(5):1214-1218.
31. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997, 278(3):212-216.
32. Psaty B.M., Smith N.L., Siscovick D.S., et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997, 277(9):739-745.
33. Dhalla A.K., Hill M.F., Singal P.K. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996, 28(2):506-514.
34. Lob H.E., Marvar P.J., Guzik T.J., et al. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 2010, 55(2):277-283. 276p following 283.
35. Peterson J.R., Burmeister M.A., Tian X., et al. Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II. Hypertension 2009, 54(5):1106-1114.
36. Jackson E.K., Gillespie D.G., Zhu C., et al. Alpha2-adrenoceptors enhance angiotensin II-induced renal vasoconstriction: role for NADPH oxidase and RhoA. Hypertension 2008, 51(3):719-726.
37. Carlstrom M., Persson A.E. Important role of NAD(P)H oxidase 2 in the regulation of the tubuloglomerular feedback. Hypertension 2009, 53(3):456-457.
38. Gongora M.C., Qin Z., Laude K., et al. Role of extracellular superoxide dismutase in hypertension. Hypertension 2006, 48(3):473-481.
39. Lavi S., Yang E.H., Prasad A., et al. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 2008, 51(1):127-133.
40. Sabri A., Hughie H.H., Lucchesi P.A. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003, 5(6):731-740.
41. Wei S., Rothstein E.C., Fliegel L., et al. Differential MAP kinase activation and Na(+)/H(+) exchanger phosphorylation by H(2)O(2) in rat cardiac myocytes. Am J Physiol Cell Physiol 2001, 281(5):C1542-C1550.
42. Tanaka K., Honda M., Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 2001, 37(2):676-685.
43. Shahbaz A.U., Kamalov G., Zhao W., et al. Mitochondria-targeted cardioprotection in aldosteronism. J Cardiovasc Pharmacol 2011, 57(1):37-43.
44. Mohammed S.F., Ohtani T., Korinek J., et al. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via " nongenomic effects" Circulation 2010, 122(4):370-378.
45. Cai L., Li W., Wang G., et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002, 51(6):1938-1948.
46. Carroll R., Carley A.N., Dyck J.R., et al. Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts. Am J Physiol Endocrinol Metab 2005, 288(5):E900-E906.
47. Young M.E., Guthrie P.H., Razeghi P., et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002, 51(8):2587-2595.
48. Buchanan J., Mazumder P.K., Hu P., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146(12):5341-5349.
49. Avogaro A., Nosadini R., Doria A., et al. Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Physiol 1990, 258(4 Pt 1):E606-E618.
50. Jagasia D., Whiting J.M., Concato J., et al. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 2001, 103(13):1734-1739.
51. Utriainen T., Takala T., Luotolahti M., et al. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 1998, 41(5):555-559.
52. Iribarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103(22):2668-2673.
53. From A.M., Scott C.G., Chen H.H. Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol 2009, 103(10):1463-1466.
54. Poirier P., Bogaty P., Garneau C., et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001, 24(1):5-10.
55. From A.M., Scott C.G., Chen H.H. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010, 55(4):300-305.
56. Ingelsson E., Arnlov J., Lind L., et al. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 2006, 92(10):1409-1413.
57. Bahrami H., Bluemke D.A., Kronmal R., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008, 51(18):1775-1783.
58. Butler J., Rodondi N., Zhu Y., et al. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 2006, 47(8):1595-1602.
59. Witteles R.M., Fowler M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008, 51(2):93-102.
60. Hayat S.A., Patel B., Khattar R.S., et al. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004, 107(6):539-557.
61. Barouch L.A., Berkowitz D.E., Harrison R.W., et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003, 108(6):754-759.
62. Thandavarayan R.A., Watanabe K., Ma M., et al. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol 2008, 75(9):1797-1806.
63. Hamblin M., Friedman D.B., Hill S., et al. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol 2007, 42(4):884-895.
64. Itoh H., Doi K., Tanaka T., et al. Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. Clin Exp Pharmacol Physiol 1999, 26(7):558-560.
65. Winkler G., Lakatos P., Salamon F., et al. Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet Med 1999, 16(3):207-211.
66. Rolo A.P., Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006, 212(2):167-178.
67. Wang J., Song Y., Elsherif L., et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006, 113(4):544-554.
68. El-Omar M.M., Lord R., Draper N.J., et al. Role of nitric oxide in posthypoxic contractile dysfunction of diabetic cardiomyopathy. Eur J Heart Fail 2003, 5(3):229-239.
69. Reilly M.P., Lehrke M., Wolfe M.L., et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111(7):932-939.
70. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107(5):671-674.
71. Frankel D.S., Vasan R.S., D'Agostino R.B., et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009, 53(9):754-762.
72. Butler J., Kalogeropoulos A., Georgiopoulou V., et al. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol 2009, 29(7):1144-1149.
73. Butler J., Kalogeropoulos A., Georgiopoulou V., et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008, 1(2):125-133.
74. Leszek P., Korewicki J., Klisiewicz A., et al. Reduced myocardial expression of calcium handling protein in patients with severe chronic mitral regurgitation. Eur J Cardiothorac Surg 2006, 30(5):737-743.
75. Mulieri L.A., Leavitt B.J., Martin B.J., et al. Myocardial force-frequency defect in mitral regurgitation heart failure is reversed by forskolin. Circulation 1993, 88(6):2700-2704.
76. Oral H., Sivasubramanian N., Dyke D.B., et al. Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation. Circulation 2003, 107(6):831-837.
77. Chen M.C., Chang J.P., Liu W.H., et al. Increased serum oxidative stress in patients with severe mitral regurgitation: a new finding and potential mechanism for atrial enlargement. Clin Biochem 2009, 42(10-11):943-948.
78. Ahmed M.I., Gladden J.D., Litovsky S.H., et al. Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%. J Am Coll Cardiol 2010, 55(7):671-679.
79. Sugiyama S., Okada Y., Sukhova G.K., et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001, 158(3):879-891.
80. Ronald J.A., Chen J.W., Chen Y., et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009, 120(7):592-599.
81. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108(12):1440-1445.
82. Mocatta T.J., Pilbrow A.P., Cameron V.A., et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007, 49(20):1993-2000.
83. Morrow D.A., Sabatine M.S., Brennan M.L., et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008, 29(9):1096-1102.
84. Scirica B.M., Sabatine M.S., Jarolim P., et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial. Eur Heart J 2011, 32(6):697-705.
85. Ward N.C., Hodgson J.M., Puddey I.B., et al. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med 2004, 36(2):226-232.
86. Redon J., Oliva M.R., Tormos C., et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003, 41(5):1096-1101.
87. Desai R.V., Ahmed M.I., Fonarow G.C., et al. Effect of serum insulin on the association between hyperuricemia and incident heart failure. Am J Cardiol 2010, 106(8):1134-1138.
88. Werns S.W., Shea M.J., Mitsos S.E., et al. Reduction of the size of infarction by allopurinol in the ischemic-reperfused canine heart. Circulation 1986, 73(3):518-524.
89. Askari A.T., Brennan M.L., Zhou X., et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003, 197(5):615-624.
90. Coghlan J.G., Flitter W.D., Clutton S.M., et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994, 107(1):248-256.
91. Coetzee A., Roussouw G., Macgregor L. Failure of allopurinol to improve left ventricular stroke work after cardiopulmonary bypass surgery. J Cardiothorac Vasc Anesth 1996, 10(5):627-633.
92. Taggart D.P., Young V., Hooper J., et al. Lack of cardioprotective efficacy of allopurinol in coronary artery surgery. Br Heart J 1994, 71(2):177-181.
93. Fonarow G.C., Wright R.S., Spencer F.A., et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005, 96(5):611-616.
94. Tang W.H., Francis G.S. Statin treatment for patients with heart failure. Nat Rev Cardiol 2010, 7(5):249-255.
95. Saab F.A., Petrina M., Kline-Rogers E., et al. Early statin therapy in elderly patients presenting with acute coronary syndrome causing less heart failure. Indian Heart J 2006, 58(4):321-324.
96. Sakamoto T., Kojima S., Ogawa H., et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006, 97(8):1165-1171.
97. Brown J.H., Del Re D.P., Sussman M.A. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006, 98(6):730-742.
98. Lipinski M.J., Cauthen C.A., Biondi-Zoccai G.G., et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009, 104(12):1708-1716.
99. Scirica B.M., Morrow D.A., Cannon C.P., et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006, 47(11):2326-2331.
100. Strandberg T.E., Holme I., Faergeman O., et al. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am J Cardiol 2009, 103(10):1381-1385.
101. Stephens N.G., Parsons A., Schofield P.M., et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347(9004):781-786.
102. Rapola J.M., Virtamo J., Ripatti S., et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997, 349(9067):1715-1720.
103. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356(9237):1213-1218.
104. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354(9177):447-455.
105. Yusuf S., Dagenais G., Pogue J., et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):154-160.
106. Lonn E., Bosch J., Yusuf S., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005, 293(11):1338-1347.
107. Shirpoor A., Salami S., Khadem-Ansari M.H., et al. Cardioprotective effect of vitamin E: rescues of diabetes-induced cardiac malfunction, oxidative stress, and apoptosis in rat. J Diabetes Complications 2009, 23(5):310-316.
108. Ren J., Dominguez L.J., Sowers J.R., et al. Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes 1996, 45(12):1822-1825.
109. Von Bibra H., Diamant M., Scheffer P.G., et al. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res 2008, 5(4):310-318.
110. Tousoulis D., Antoniades C., Vassiliadou C., et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005, 7(7):1126-1132.
111. Bowry V.W., Ingold K.U., Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 1992, 288(Pt 2):341-344.